Valuation dashboard for Protagonist Therapeutics, Inc. (PTGX) with P/E N/A, P/B 8.71, EV/EBITDA -42.43 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders.
Analysis Summary
Protagonist Therapeutics, Inc. reported revenue of $46.0M in the most recent fiscal year, growing at a 5-year CAGR of 10.0%.
Trailing-twelve-month margins: gross margin 97.3%, operating margin -343.6%, net margin -282.8%.
At the current price of $142.84, PTGX has negative trailing earnings (P/E not meaningful) and an ROE of -21.17%. Market capitalisation stands at $9.2B.
Balance sheet quality for PTGX: current ratio of 12.7. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 8.71 |
| EV / EBITDA | -42.43 |
| Dividend Yield | 0.00% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| PTGX | Protagonist Therapeutics, Inc. | $9.2B | 8.71 | -21.2% | |
| KYMR | Kymera Therapeutics, Inc. | $9.6B | 7.56 | ||
| ACLX | Arcellx, Inc. | $6.7B | 16.10 | ||
| PTCT | PTC Therapeutics, Inc. | $5.6B | |||
| ALKS | Alkermes plc | $7.7B | 112.07 | 4.16 | |
| IMVT | Immunovant, Inc. | $7.5B | 9.99 | ||
| CRNX | Crinetics Pharmaceuticals, Inc. | $9.0B | 7.52 | -44.2% | |
| NAMS | NewAmsterdam Pharma Company N.V. | $2.5B | 5.45 | -29.8% |
Price
| Price | $142.84 |
| Market Cap | $9.2B |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -21.17% |
| Return on Invested Capital | -25.23% |
| Return on Assets | -19.43% |
| Gross Margin | 97.34% |
| Operating Margin | -343.63% |
| Net Margin | -282.83% |
Related companies: ACLX · AKRO · ALKS · CRNX · IMVT · KYMR · NAMS
Explore sector: Healthcare · Biotechnology
More sections of PTGX: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks